[{"address1": "Sant Ferran 74", "city": "Cornell\u00e0 de Llobregat", "zip": "08940", "country": "Spain", "phone": "34 93 515 13 13", "fax": "34 93 377 40 28", "website": "https://www.oryzon.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornell\u00e0 de Llobregat, Spain.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Dr. Carlos Manuel Buesa Arjol", "title": "Co-Founder, Chairman, CEO & President", "fiscalYear": 2015, "totalPay": 64827, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Enric Rello Condomines", "title": "Director of Operations, COO & CFO", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jordi Xaus Pey", "title": "Chief Scientific Officer", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Xavier Perpinya Ribera", "title": "Head of Internal Audit & Compliance", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Emili Torrell Cortada", "title": "Chief Business Development Officer", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Neus Virgili Bernado", "title": "Chief Intellectual Property Officer", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael Thomas Ropacki Ph.D.", "title": "Chief Medical Officer of CNS", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sonia Paloma Gutierrez Bezon", "title": "Chief of Clinical Operations", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Augusto Pinel Rubio", "title": "Secretary", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1451520000, "maxAge": 86400, "priceHint": 4, "previousClose": 1.41, "open": 1.41, "dayLow": 1.41, "dayHigh": 1.41, "regularMarketPreviousClose": 1.41, "regularMarketOpen": 1.41, "regularMarketDayLow": 1.41, "regularMarketDayHigh": 1.41, "beta": 0.623, "volume": 300, "regularMarketVolume": 300, "averageVolume": 16, "averageVolume10days": 100, "averageDailyVolume10Day": 100, "bid": 1.55, "ask": 2.55, "marketCap": 132126440, "fiftyTwoWeekLow": 1.41, "fiftyTwoWeekHigh": 2.26, "priceToSalesTrailing12Months": -39.14223, "fiftyDayAverage": 1.4828, "twoHundredDayAverage": 1.6801, "currency": "USD", "enterpriseValue": 129456600, "floatShares": 53131877, "sharesOutstanding": 63436100, "heldPercentInsiders": 0.1557, "heldPercentInstitutions": 0.0073900004, "bookValue": 1.375, "priceToBook": 1.4036363, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": -0.89, "netIncomeToCommon": -3929807, "trailingEps": -0.07, "enterpriseToRevenue": -38.351, "enterpriseToEbitda": -6.695, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "ORYZF", "underlyingSymbol": "ORYZF", "shortName": "ORYZON GENOMICS SA", "longName": "Oryzon Genomics S.A.", "firstTradeDateEpochUtc": 1608042600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fe30afed-2e89-3070-9140-bb2eb7339d5f", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.93, "recommendationKey": "none", "totalCash": 10076217, "totalCashPerShare": 0.16, "ebitda": -19335168, "totalDebt": 18056156, "quickRatio": 0.949, "currentRatio": 0.95, "totalRevenue": -3375547, "debtToEquity": 20.871, "revenuePerShare": -0.054, "returnOnAssets": -0.11305001, "returnOnEquity": -0.047620002, "earningsGrowth": -0.895, "revenueGrowth": -0.451, "operatingMargins": 0.19586, "financialCurrency": "EUR", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]